Integrated analysis of miRNA and transcription factor gene expression profiles associated with anti-tuberculosis treatment responses Authors: Heechul Park, Eun Ju Lee, Sunyoung Park, Sung-Bae Park, Yun-Jeong Kang, Jiyoung Lee, Jake Whang, Young Ae Kang, Sunghyun Kim, Hyejon Lee, Jungho Kim Published: 2026 ABSTRACT BackgroundTuberculosis (TB) is a severe respiratory illness that can lead to opportunistic infections in individuals with weakened immune systems. Accurate diagnosis and monitoring of treatment responses are essential. In this study, we analyzed the miRNA and mRNA profiles of 12 patients with active TB (ATB) before and after treatment.MethodsWe identified differentially expressed (DE) microRNAs (miRNAs) and messenger RNAs (mRNAs), and investigated the relationship between the expression of miRNAs and their target mRNAs. We validated the selected miRNA levels using quantitative reverse transcription polymerase chain reaction (qRT-PCR).ResultsAfter six months of treatment, miRNA profiling of patients with ATB revealed nine miRNAs with altered expression levels. Anti-TB treatment restored miR-223-3p, miR-6787-3p, miR-338-5p, miR-1273h-3p, miR-1288-3p, miR-200c-3p, miR-3074-3p, miR-433-3p, and miR-200b-3p levels to those observed in healthy controls. We conducted qRT-PCR to verify the top nine DE miRNAs using an additional set of 22 blood samples. The results showed that all nine DE miRNAs exhibited decreased expression after the completion of therapy. mRNA sequencing was performed on the same blood samples. This analysis confirmed the significant DE of 75 mRNAs, of which 13 (AFF3, NT5C1B, HIC2, SPATA25, ZFYVE9, HTR7, LRRC8E, METTL2A, PLD4, RGS5, EME2, TIGD5, and PEG10) interacted with the miRNAs pre-analyzed using the miRWalk miRNA target prediction and analysis program.ConclusionThe DE miRNAs identified in this study may serve as potential biomarkers for monitoring the therapeutic efficacy of ATB.Clinical trial numberNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-026-13676-x. Background Tuberculosis (TB) is a contagious global health burden caused by the acid-fast bacterium Mycobacterium tuberculosis (MTB) [1, 2]. According to the World Health Organization, TB caused approximately 1.5 million deaths worldwide in 2020, ranking as the second leading infectious cause of mortality after COVID-19 [3]. Ongoing challenges include disease recurrence, such as relapse and reinfection, as well as the increasing global prevalence of multidrug-resistant and extensively drug-resistant TB [4, 5]. Early diagnosis and effective treatment are critical for improving TB outcomes. Although substantial progress has been made in understanding and treating Mycobacterium tuberculosis infection [6, 7], achieving the World Health Organization’s targets to reduce TB deaths and incidence by 2035 will require new interventions, including therapies targeting drug-resistant TB, shortened treatment regimens, and more effective vaccines [8, 9]. In this context, the development of biomarkers capable of identifying active TB and predicting treatment response is essential, as such markers could enable early detection of treatment failure or drug resistance and serve as surrogate endpoints in drug and vaccine trials, thereby reducing follow-up duration [10–13]. Typically, the conversion of sputum culture after two months of anti-TB drug therapy serves as a predictive measure of treatment response in patients [14]. Nevertheless, this method is not applicable to individuals with extrapulmonary or culture-negative pulmonary TB, and resource-limited settings frequently lack laboratories that can perform sputum cultures [15, 16]. Recently, a growing body of research has focused on microRNAs (miRNAs) as biomarkers associated with TB that serve as standards for assessing TB progression and treatment outcomes [17]. miRNAs are short non-coding RNAs consisting of approximately 22 nucleotides that are active in post-transcriptional regulation and suppress gene expression by binding to complementary messenger RNA (mRNA) sequences [18]. Studies have validated the involvement of miRNAs in the onset and progression of TB [19]. The potential of serum miRNA levels as diagnostic markers has spurred researchers to assess their clinical applicability in various conditions, including TB and non-tuberculous mycobacterial infections [20]. Previous studies have suggested that specific miRNAs influence the host immune response to MTB [21], with most showing dysregulation following MTB infection [22]. Although the roles of miRNAs in TB have been established, their diagnostic or prognostic potential in clinical settings remains incompletely explored. Successful identification of diagnostic biomarkers and therapeutic targets has evolved alongside advancements in genetic analysis methods and bioinformatics [23]. Moreover, miRNAs play a role in regulating numerous genes and influence activators or suppressors within biological signaling networks [24]. Therefore, a thorough examination of miRNAs and identification of crucial target genes can offer significant prospects for the diagnosis and treatment of diseases. The objective of this study was to investigate whether the levels of miRNAs and their potential target mRNAs changed during anti-TB drug treatment in patients with ATB in South Korea, a country with an intermediate TB burden and a low incidence of HIV/AIDS. What sets this study apart is the simultaneous analysis of miRNAs and mRNA within the same blood sample, which provides a more integrated and precise understanding of the dynamic regulatory interactions that occur during treatment. In this context, the present study aimed to identify treatment-associated miRNA signatures and their regulatory networks by integrating miRNA and mRNA expression profiles before and after anti-tuberculosis therapy. Methods Study participants Blood samples were collected from patients attending Yonsei University Severance Hospital, a tertiary referral center located in Seoul, Republic of Korea, from January 2016 to September 2019. The Institutional Ethics Committee of Yonsei University Severance Hospital approved the study (IRB No. 4-2014-1108), and written consent was obtained from all participants for the identification of TB biomarkers. Participants with any acute or chronic illnesses, prior history of ATB, or symptoms suggestive of TB were excluded. The study population was categorized into two groups: the ATB and healthy control (HC) groups. ATB: Patients were diagnosed with ATB based on microbiological and pathological evidence. Confirmation of the ATB diagnosis relied on a positive MTB culture result from respiratory specimens or the presence of caseous granulomas in lung tissue. Additionally, cases of clinical ATB characterized by negative mycobacterial culture findings and positive clinical and radiological responses to anti-TB medications were included.HCs were required to test negative for TB based on the QuantiFERON-TB Gold In-Tube Test (QFT-GIT) and chest radiography with no prior history of TB. They did not exhibit ATB symptoms and had not recently come in contact with individuals diagnosed with ATB. ATB: Patients were diagnosed with ATB based on microbiological and pathological evidence. Confirmation of the ATB diagnosis relied on a positive MTB culture result from respiratory specimens or the presence of caseous granulomas in lung tissue. Additionally, cases of clinical ATB characterized by negative mycobacterial culture findings and positive clinical and radiological responses to anti-TB medications were included. ATB: Patients were diagnosed with ATB based on microbiological and pathological evidence. Confirmation of the ATB diagnosis relied on a positive MTB culture result from respiratory specimens or the presence of caseous granulomas in lung tissue. Additionally, cases of clinical ATB characterized by negative mycobacterial culture findings and positive clinical and radiological responses to anti-TB medications were included. HCs were required to test negative for TB based on the QuantiFERON-TB Gold In-Tube Test (QFT-GIT) and chest radiography with no prior history of TB. They did not exhibit ATB symptoms and had not recently come in contact with individuals diagnosed with ATB. HCs were required to test negative for TB based on the QuantiFERON-TB Gold In-Tube Test (QFT-GIT) and chest radiography with no prior history of TB. They did not exhibit ATB symptoms and had not recently come in contact with individuals diagnosed with ATB. Patients with ATB received treatment in line with the national guidelines that align with the WHO DOTS protocols. Blood samples were collected before the initiation of treatment and again at 2 and 6 months. Standard Category 1 therapy included a 2-month regimen of isoniazid, rifampicin, ethambutol, and pyrazinamide, followed by 4 months of isoniazid and rifampicin. Patients were deemed cured if, after standard treatment, they had a negative sputum culture (for sputum smear-negative/culture-negative TB) or if their radiological findings showed the disappearance of lesions or significant improvement. AFB smears and culture To detect acid-fast bacilli (AFB), sputum samples were subjected to auramine-rhodamine fluorescence staining, which was confirmed using the Ziehl–Neelsen method. Mycobacterial cultures were performed using both liquid and solid culture media, and the presence of the M. tuberculosis complex was verified by duplex PCR using the Advansure TB/NTM real-time PCR assay (LG Chemistry, Seoul, Korea). All procedures involving mycobacterial culture and AFB smear examination of sputum samples were conducted within a Class 2 biosafety cabinet that adhered to the local and national regulations on containment equipment. QFT-GIT The QFT-GIT test, a commercial TB-specific interferon-gamma release assay (QIAGEN, Hilden, Germany), was performed according to the manufacturer’s guidelines. Briefly, 1 mL of whole blood was collected into three QFT-GIT collection tubes: one for no stimulation (negative control), one for MTB-specific peptide stimulation (ESAT-6, CFP-10, and TB7.7), and one for mitogen stimulation (positive control). Samples were incubated for 16–24 h at 37 °C. Plasma was separated by centrifugation at 3000 × g for 15 min and stored at -80 °C until analysis. The concentration of IFN-γ was determined using a QFT-GIT enzyme-linked immunosorbent assay kit following the manufacturer’s instructions. The QFT-GIT test results were interpreted using QFT-GIT software version 2.62 (QIAGEN). Total RNA isolation At the time of diagnosis (T0), at 2 months (T2; during treatment) and 6–9 months post-treatment (T6; completion of treatment), three milliliters of whole blood were collected into PAXgene Blood RNA tubes (QIAGEN) and preserved at -80 °C. Following the manufacturer’s protocol, total RNAs were extracted from the samples using the PAXgene Blood miRNA Kit (QIAGEN). The RNA concentration was determined using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA), and RNA integrity was assessed using a BioAnalyzer 2100 (Agilent, Santa Clara, USA). Only samples with an RNA integrity number (RIN) greater than or equal to 7.0 were selected for sequencing. These RNA samples were stored at -80 °C until further use. MicroRNA sequencing The NEBNext Multiplex Small RNA Library Prep Kit (Illumina, San Diego, CA, USA) was used to prepare small RNA libraries according to the manufacturer’s guidelines. In summary, the process involved generating an RNA sequencing library on the Illumina NextSeq500 platform through steps including complementary DNA (cDNA) amplification, end-repair, adenylation of 3’ ends, adapter ligation, and subsequent amplification. mRNA sequencing RNA libraries were prepared using TruSeq Stranded Total RNA with the RiboZero Globin kit (Illumina) according to the manufacturer’s instructions. In brief, this involved generating an RNA sequencing library on the Illumina HiSeq2500 platform through steps such as cDNA amplification, end-repair, adenylation of 3’ ends, adapter ligation, and subsequent amplification. Target gene prediction and gene set enrichment analysis. The online tool miRWalk (http://mirwalk.umm.uni-heidelberg.de/) was used to predict the genes potentially regulated by the identified differentially expressed (DE) miRNAs. For gene set enrichment analysis, the target genes in the network were analyzed using Enrichr-KG (https://maayanlab.cloud/enrichr-kg) [25]. qRT-PCR validation To assess the expression of the identified miRNA panel, blood samples were treated with 500 µL of RNA/DNA stabilization reagent (Roche Diagnostics, Mannheim, Germany). Subsequently, RNA was extracted using the MagNA Pure LC RNA Isolation Kit-High Performance Kit (Roche Diagnostics), according to the manufacturer’s guidelines. Following this, cDNA of the specified miRNAs was synthesized using the miRCURY LNA RT Kit (QIAGEN), according to the manufacturer’s protocols. The temperature regimen for cDNA synthesis was set at 42 °C for 60 min, followed by 95 °C for 5 min. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed using the miRCURY LNA miRNA PCR assay. The PCR cycling conditions included an initial denaturation step at 95 °C for 2 min, followed by 40 cycles of denaturation at 95 °C for 10 s and annealing/extension at 56 °C for 1 min. The qRT-PCR assays were performed using a CFX96 Real-time PCR System Detector (Bio-Rad, Hercules, CA, USA) with duplicate samples for each experiment. Negative controls were used to monitor the reagent contamination for each primer pair. Data analysis employed the comparative threshold cycle (ΔCt) method, using RNU44 as the endogenous control, where\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\boldsymbol{\varDelta\:}\boldsymbol{C}\boldsymbol{t}\:={\boldsymbol{C}\boldsymbol{t}}_{\boldsymbol{t}\boldsymbol{a}\boldsymbol{r}\boldsymbol{g}\boldsymbol{e}\boldsymbol{t}\:\boldsymbol{m}\boldsymbol{i}\boldsymbol{R}\boldsymbol{N}\boldsymbol{A}\:}-{\boldsymbol{C}\boldsymbol{t}}_{\boldsymbol{e}\boldsymbol{n}\boldsymbol{d}\boldsymbol{o}\boldsymbol{g}\boldsymbol{e}\boldsymbol{n}\boldsymbol{o}\boldsymbol{u}\boldsymbol{s}\:\boldsymbol{c}\boldsymbol{o}\boldsymbol{n}\boldsymbol{t}\boldsymbol{r}\boldsymbol{o}\boldsymbol{l}}$$\end{document} Statistical analysis Data were analyzed using IBM SPSS Statistics for Windows, Version 21.0 (IBM, Armonk, NY, USA), GraphPad Prism software, Version 6.0 (GraphPad, La Jolla, CA, USA), and MeV 4.9 (The Perl Foundation). Group comparisons were performed using the Mann-Whitney U test. Correlation analysis between the miRNAs and their potential target mRNA was conducted using Spearman’s correlation coefficient. The optimal cutoff values of miRNAs for therapeutic response assessment were analyzed using receiver operating characteristic curve analysis (Figure S1). The statistical significance level was set at p < 0.05 for all analyses. Results Characteristics of study participants The demographic and clinical characteristics of the study participants are summarized in Table 1. In the discovery set, the average age of patients with ATB and HCs was 41.0 years (± 19.6) and 34.4 years (± 7.2), respectively. Males accounted for 66.7% (8 out of 12) of the patients and 60.0% (6 out of 10) of the HC group. Bacille Calmette-Guérin (BCG) scars were observed in 75.0% and 90.0% of the patients and HCs, respectively. No significant differences in demographic characteristics were observed between the two groups. Table 1Characteristics of study participantsCharacteristicsDiscovery setValidation setPatients with ATB(n = 12)Treated TB(n = 12)HC(n = 10)Patients with ATB(n = 5)Treated TB(n = 5)HC(n = 17)Sex (male, %)8 (66.7%)8 (66.7%)6 (60.0%)4 (80.0%)4 (80.0%)1 (5.9%)Age (mean ± SD)41.0 ± 19.641.0 ± 19.634.4 ± 7.246.2 ± 17.646.2 ± 17.644.7 ± 17.2BCG scar (%)9 (75.0%)9 (75.0%)9 (90.0%)2 (40.0%)2 (40.0%)14 (82.3%)AFB stain positive2 (16.7%)0 (0.0%)1 (20.0%)0 (0.0%)Culture positive10 (83.3%)0 (0.0%)5 (100.0%)0 (0.0%)QFT-GIT resultPositive12 (100.0%)11 (91.6%)0 (0.0%)5 (100.0%)5 (100.0%)0 (0.0%)Intermediate0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)Negative0 (0.0%)1 (8.3%)10 (100.0%)0 (0.0%)0 (0.0%)17 (100.0%) Table 1Characteristics of study participantsCharacteristicsDiscovery setValidation setPatients with ATB(n = 12)Treated TB(n = 12)HC(n = 10)Patients with ATB(n = 5)Treated TB(n = 5)HC(n = 17)Sex (male, %)8 (66.7%)8 (66.7%)6 (60.0%)4 (80.0%)4 (80.0%)1 (5.9%)Age (mean ± SD)41.0 ± 19.641.0 ± 19.634.4 ± 7.246.2 ± 17.646.2 ± 17.644.7 ± 17.2BCG scar (%)9 (75.0%)9 (75.0%)9 (90.0%)2 (40.0%)2 (40.0%)14 (82.3%)AFB stain positive2 (16.7%)0 (0.0%)1 (20.0%)0 (0.0%)Culture positive10 (83.3%)0 (0.0%)5 (100.0%)0 (0.0%)QFT-GIT resultPositive12 (100.0%)11 (91.6%)0 (0.0%)5 (100.0%)5 (100.0%)0 (0.0%)Intermediate0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)Negative0 (0.0%)1 (8.3%)10 (100.0%)0 (0.0%)0 (0.0%)17 (100.0%) Characteristics of study participants Twenty-two additional blood samples were included in the validation set, including those of five patients who had been diagnosed with ATB and completed their treatment (six months post-treatment) and 17 HCs (Table 1). Profiles of miRNA and mRNA in response to treatment To identify potential miRNA candidates for therapeutic response assessment using a transcriptome-based approach, we extracted total RNAs from the blood samples of the study participants, including a complete set from patients with ATB who had completed a six-month treatment course in the discovery set. Through miRNA sequencing, we identified potential DE miRNAs and generated a heat map to categorize these 50 miRNAs based on patients’ treatment status (Fig. 1A). Subsequently, 19 DE miRNAs were identified using volcano plot analysis employing specific criteria (log2 (fold change) > 1.0 or < -1.0; p < 0.01) (Fig. 1B). The direction of change was defined as the difference between the mean expression levels of treated TB (T6) and active TB (T0) samples, allowing identification of. Fig. 1Heat map and volcano plot of differentially expressed miRNAs in the whole blood of patients with active tuberculosis (T0) and those who completed anti-tuberculosis treatment (T6). (A) A heatmap illustrating 50 significantly differentially expressed miRNAs between the T0 and T6 patients, determined through a Pearson correlation analysis with a significance level of p < 0.01 using hierarchical clustering; the red dots indicate upregulated miRNAs, while the blue dots indicate downregulated miRNAs. (B) A volcano plot comparing miRNAs between the T0 and T6 patients; the x-axis represents the difference between the mean expression values of the T6 and T0 groups, and significant thresholds of p-values (< 0.01) and log2 (fold change) are indicated using a red line (> 1.0) and a blue line (< -1.0), respectively. In the volcano plot, Negative values indicate miRNAs that are downregulated after treatment, whereas positive values indicate miRNAs that are upregulated following treatment Heat map and volcano plot of differentially expressed miRNAs in the whole blood of patients with active tuberculosis (T0) and those who completed anti-tuberculosis treatment (T6). (A) A heatmap illustrating 50 significantly differentially expressed miRNAs between the T0 and T6 patients, determined through a Pearson correlation analysis with a significance level of p < 0.01 using hierarchical clustering; the red dots indicate upregulated miRNAs, while the blue dots indicate downregulated miRNAs. (B) A volcano plot comparing miRNAs between the T0 and T6 patients; the x-axis represents the difference between the mean expression values of the T6 and T0 groups, and significant thresholds of p-values (< 0.01) and log2 (fold change) are indicated using a red line (> 1.0) and a blue line (< -1.0), respectively. In the volcano plot, Negative values indicate miRNAs that are downregulated after treatment, whereas positive values indicate miRNAs that are upregulated following treatment miRNAs whose expression decreased or increased following anti-tuberculosis therapy Among the identified DE miRNAs, the top nine, including miR-223-3p, miR-338-5p, miR-6787-3p, miR-1273h-3p, miR-1288-3p, miR-200c-3p, miR-3074-3p, miR-433-3p, and miR-200b-3p, tended to decrease within two months of treatment and continued to trend towards HC levels after completion of treatment (Fig. 2). The clinical performance of these miRNAs in response to treatment was superior or comparable to that of other approaches (sputum smear, sputum culture, and QFT-GIT test; Fig. 3 and S1). In addition to longitudinal comparisons within tuberculosis patients, baseline expression levels of the candidate miRNAs were also compared between active TB patients (T0) and healthy controls (HC). Most of the identified miRNAs exhibited significantly higher expression in T0 samples than in HC, indicating disease-associated upregulation at diagnosis. Fig. 2The expression levels of the top nine miRNAs in patients with active tuberculosis collected at the time of diagnosis (T0), after two months of anti-tuberculosis treatment (T2), after the completion of anti-tuberculosis treatment (T6), and healthy controls. The expression levels of the top nine differentially expressed miRNAs—miR-223-3p, miR-338-5p, miR-6787-3p, miR-1273h-3p, miR-1288-3p, miR-200c-3p, miR-3074-3p, miR-433-3p, and miR-200b-3p—were assessed in patients with ATB at diagnosis (T0) and post-therapy (T2 and T6). The blue dotted lines represent the mean miRNA expression levels in healthy controls. Data are presented as mean ± standard error of the mean. *p < 0.05 and **p 0.001 indicate comparisons between T0 and T6, whereas #p < 0.001 denotes comparisons between T0 and healthy controls (HC) The expression levels of the top nine miRNAs in patients with active tuberculosis collected at the time of diagnosis (T0), after two months of anti-tuberculosis treatment (T2), after the completion of anti-tuberculosis treatment (T6), and healthy controls. The expression levels of the top nine differentially expressed miRNAs—miR-223-3p, miR-338-5p, miR-6787-3p, miR-1273h-3p, miR-1288-3p, miR-200c-3p, miR-3074-3p, miR-433-3p, and miR-200b-3p—were assessed in patients with ATB at diagnosis (T0) and post-therapy (T2 and T6). The blue dotted lines represent the mean miRNA expression levels in healthy controls. Data are presented as mean ± standard error of the mean. *p < 0.05 and **p 0.001 indicate comparisons between T0 and T6, whereas #p < 0.001 denotes comparisons between T0 and healthy controls (HC) Fig. 3Clinical assessment of the nine miRNAs for therapeutic response Clinical assessment of the nine miRNAs for therapeutic response We performed a detailed comparison of mRNA profiles between patients diagnosed with ATB and those who completed treatment (6 months post-treatment) using stringent criteria (p-value < 0.01 and log2 (fold change) > 1.0 or < -1.0). A heatmap illustrating the expression profiles of representative differentially expressed mRNAs is provided in Figure S2A. This analysis identified 75 upregulated mRNAs as potential targets of the DE miRNAs (Figure S2B). Target prediction for significantly differentially expressed miRNA To explore the potential targets of the top nine dysregulated miRNAs, we used the miRWalk database (http://mirwalk.umm.uni-heidelberg.de/; accessed April 24, 2024) to predict target genes associated with each miRNA. Among the 75 mRNA transcripts that were up-regulated in our RNA sequencing data, 30 genes were identified, including AFF3, ANKRD23, DDTL, DEPTOR, DTX1, EME2, FAAP100, GPR135, HIC2, HPCAL4, HTR7, IMMP2L, LRRC8E, LYSMD4, METTL2A, NT5C1B, NTMT1, PDE7B, PEG10, PLD4, RGS5, SEMA4G, SMCO3, SPATA25, SPHK2, TIGD5, TMEM134, TMEM139, UBE3D, and ZFYVE9 (Table S1 and S2). To further explore the potential biological functions of the 30 candidate target genes, we conducted a gene set enrichment analysis across various libraries, including the Mouse Genome Informatics (MGI) mammalian phenotype, Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Ontology (GO) biological systems, using Enrichr-KG (Fig. 4, Table S3). The candidate genes were linked to renal glomerular immunoglobulin deposits (MP: 0020519), the Fanconi anemia pathway (KEGG), spleen hyperplasia (MP: 0000693), negative regulation of histone deacetylation (GO: 0031064), regulation of cytochrome-c oxidase activity (GO: 1904959), positive regulation of histone H3-K9 acetylation (GO: 2000617), processing proteins involved in mitochondrial targeting (GO: 0006627), cyclic-GMP-AMP transmembrane import across the plasma membrane (GO: 0140361), increased thermal nociceptive threshold (MP: 0001973), decreased systemic arterial diastolic blood pressure (MP: 0006263), increased anti-histone antibody levels (MP: 0004796), purine metabolism (KEGG), protein export (KEGG), calcium signaling pathway (KEGG), and nicotinate and nicotinamide metabolism (KEGG). Fig. 4Gene ontology (GO) enrichment analysis of the potential target genes. Thirty potential target genes were uploaded to the Enrichr-KG database, and a significant target gene network was constructed (p < 0.05) Gene ontology (GO) enrichment analysis of the potential target genes. Thirty potential target genes were uploaded to the Enrichr-KG database, and a significant target gene network was constructed (p < 0.05) Subsequently, we conducted a correlation analysis to validate the association between the miRNAs and their respective target genes. The expression levels of each miRNA and its potential targets were examined (miR-1273h-3p for HTR7, LRRC8E, METTL2A, PLD4, and RGS5; miR-1288-3p for EME2 and TIGD5; miR-200c-3p for EME2 and PEG10; miR-223-3p for AFF3 and NT5C1B; and miR-338-5p for AFF3, HIC2, SPATA25, and ZFYVE9), revealing notable inverse correlations (Spearman’s rank correlation coefficient (r) ranging from − 0.41 to -0.63, p < 0.05; Fig. 5). Fig. 5Correlation analysis of differentially expressed miRNAs and their target mRNAs. Scatter plots depicting the correlation between differentially expressed miRNAs and their potential target genes. Data were analyzed using Spearman’s correlation coefficients. *p < 0.05, **p < 0.001, ***p < 0.0001 Correlation analysis of differentially expressed miRNAs and their target mRNAs. Scatter plots depicting the correlation between differentially expressed miRNAs and their potential target genes. Data were analyzed using Spearman’s correlation coefficients. *p < 0.05, **p < 0.001, ***p < 0.0001 Clinical verification of the response of the top nine miRNAs to treatment We further performed qRT-PCR verification of the top nine DE miRNAs using 22 additional blood samples (5 ATB and 17 HC samples). The expression levels of all nine top DE miRNAs decreased in patients with ATB after treatment. In particular, the reduced expression levels of the nine miRNAs shifted toward HC expression levels (Fig. 6). Taken together, these results demonstrate coordinated changes in miRNA and mRNA expression profiles associated with anti-tuberculosis treatment. Fig. 6Validation of the top nine miRNAs in the active TB group (T0), completed anti-TB treatment group (T6), and healthy control group. The expression levels of (A) miR-223-3p, (B) miR-338-5p, (C) miR-6787-3p, (D) miR-1273h-3p, (E) miR-1288-3p, (F) miR-200c-3p, (G) miR-3074-3p, (H) miR-433-3p, and (I) miR-200b-3p were assessed using qRT-PCR in patients with ATB both at diagnosis and after completion of therapy. Normalized ΔCt values are presented, where lower ΔCt values indicate higher miRNA expression levels. Dashed blue lines indicate average miRNA expression levels in the HC group. Data are presented as mean ± standard error of the mean Validation of the top nine miRNAs in the active TB group (T0), completed anti-TB treatment group (T6), and healthy control group. The expression levels of (A) miR-223-3p, (B) miR-338-5p, (C) miR-6787-3p, (D) miR-1273h-3p, (E) miR-1288-3p, (F) miR-200c-3p, (G) miR-3074-3p, (H) miR-433-3p, and (I) miR-200b-3p were assessed using qRT-PCR in patients with ATB both at diagnosis and after completion of therapy. Normalized ΔCt values are presented, where lower ΔCt values indicate higher miRNA expression levels. Dashed blue lines indicate average miRNA expression levels in the HC group. Data are presented as mean ± standard error of the mean Discussion Importantly, despite global advances in medical technology and TB treatment, tuberculosis remains a significant public health threat [26–28]. The increasing prevalence of multidrug-resistant and extensively drug-resistant TB, driven by complex host immune responses, underscores the limitations of current treatment monitoring strategies [29]. As sputum culture conversion at two months does not reliably predict treatment efficacy, there is a critical need for novel biomarkers to improve the assessment of treatment outcomes. MicroRNAs (miRNAs) regulate post-transcriptional gene expression and play key roles in diverse biological and pathological processes [30]. Recent studies have shown that miRNA expression profiles vary according to TB infection status, highlighting their potential utility as biomarkers for TB diagnosis, prognosis, and treatment monitoring [17, 19, 31]. In this study, a high-throughput sequencing approach using DESeq analysis was used to identify variations in mRNA and miRNA expression in patients with TB following successful anti-TB drug therapy. This study revealed that the expression levels of the identified miRNA panel, decreased in patients with TB after successful treatment with anti-TB drugs compared to their levels at the time of diagnosis. Understanding the intricate miRNA network involved in host-pathogen interactions could lead to the discovery of novel biomarkers and enhance the effectiveness of TB therapies in humans. Therefore, a regulatory network was established linking the identified miRNAs with their targets, along with correlation analyses of the predicted target genes [17–22]. The DE miRNA levels were inversely correlated with those of their potential targets (miR-1273h-3p for HTR7, LRRC8E, METTL2A, PLD4, and RGS5; miR-1288-3p for EME2 and TIGD5; miR-200c-3p for EME2 and PEG10; and miR-223-3p for AFF3 and NT5C1B). To further interpret these findings in the context of treatment response, the regulatory relationships between the identified differentially expressed miRNAs and their predicted target genes were examined. The integrative miRNA–mRNA correlation analysis revealed inverse expression patterns between several miRNAs and genes involved in immune regulation, inflammatory signaling, and cellular stress responses, suggesting potential post-transcriptional regulatory interactions during anti-tuberculosis therapy [32–34]. Importantly, many of the enriched biological pathways identified through GO analysis, including cyclic AMP signaling, nicotinate and nicotinamide metabolism, calcium signaling, and mitochondrial-associated processes, have been previously implicated in host immune modulation and metabolic adaptation during tuberculosis treatment [35–39]. These observations suggest that the altered miRNA expression profiles observed after successful therapy may reflect dynamic host immune and metabolic remodeling in response to bacterial clearance, rather than direct drug–target effects [32, 38]. Collectively, these miRNA–mRNA regulatory networks provide biologically plausible links between treatment-associated molecular changes and pathways relevant to tuberculosis pathophysiology, supporting their potential relevance as biomarkers of treatment response [17, 19, 32]. Differential expression of miRNAs and mRNAs alone does not indicate a causal role in treatment response. The observed transcriptomic changes represent associative molecular signatures during anti-tuberculosis therapy and likely reflect host immune and metabolic adaptations accompanying bacterial clearance. Therefore, these findings should be considered hypothesis-generating, and functional studies are required to establish causal relationships. GO analysis of identified target genes was performed using Enrichr-KG. These target genes are associated with various biological processes, including renal glomerular immunoglobulin deposits, the Fanconi anemia pathway, spleen hyperplasia, negative regulation of histone deacetylation, and regulation of cytochrome-c oxidase activity. Additionally, they are involved in the positive regulation of histone H3-K9 acetylation, processing of proteins related to mitochondrial targeting, cyclic-GMP-AMP transmembrane import across the plasma membrane, increased thermal nociceptive threshold, decreased systemic arterial diastolic blood pressure, elevated anti-histone antibody levels, purine metabolism, protein export, calcium signaling, and metabolism of nicotinate and nicotinamide. Cyclic AMP (cAMP) is a well-known secondary messenger that transmits signals from cellular receptors to downstream effectors [40]. MTB invests substantial genetic resources in cAMP synthesis, detection, and breakdown. According to a study by Wong et al., cAMP is vital for regulating intrinsic multidrug resistance and fatty acid metabolism in MTB H37Rv [39]. Furthermore, nicotinamide is recognized for its wide-ranging effects on host inflammatory and metabolic processes, primarily owing to its anti-inflammatory actions. These include decreased secretion of pro-inflammatory cytokines [41–43], disruption of M1 macrophage differentiation [44], and inhibition of macrophage chemotaxis [44–46]. Simmons et al. showed that nicotinamide restricts the replication of both MTB and BCG in macrophages [47]. These findings may enhance future research on anti-TB therapeutic approaches. Recent studies have identified important miRNAs involved in TB. Functional investigations of TB infection status have been conducted on miR-223-3p, miR-200c-3p, and miR-200b-3p, all of which exhibited notable findings in our study. miR-223 is an immune modulator, and its role as a potential biomarker in various infectious diseases has been explored, particularly in lung conditions such as TB and COVID-19 [48, 49]. Xi et al. demonstrated that miR-223 is significantly upregulated in peripheral blood macrophages after MTB infection, contributing to the inhibition of macrophage apoptosis [50]. In the present study, miR-223-3p exhibited significant differential expression between patients receiving anti-TB treatment and those who did not, possibly indicating its involvement in immune response modulation by anti-TB medications. AFF3, which showed an inverse correlation with miR-223-3p in this study, is highly expressed in lymphocytes and directly regulates acquired immunity. It is involved in immunoglobulin class switch recombination and is essential for handling infections and inflammatory tissue damage [51]. Similarly, the diagnostic miRNA miR-200 family, known for its role in cancer and infectious diseases, plays a significant role in the epithelial-mesenchymal transition process and drug resistance [52]. miR-200c-3p showed notable results in the correlation analysis between EME2 and PEG10. Thus, the roles of the most notable DE miRNAs identified in this study have been examined previously; however, their clinical significance has not yet been thoroughly explored. Preliminary investigations revealed notable alterations in the nine key miRNAs levels in response to MTB infection, indicating a significant modulation of miRNA expression during the course of therapy. The expression levels of these nine miRNAs were evaluated using qRT-PCR in a longitudinal validation study using additional samples collected before and after treatment. Future studies should address the limitations of the present work by including larger, multicenter cohorts to improve generalizability. In addition, the inclusion of patients with other lung diseases as control groups will be important to evaluate the specificity of the identified miRNAs for tuberculosis. Functional validation studies are also warranted to clarify the mechanistic roles of these miRNAs in treatment response. Conclusions In conclusion, we propose that miR-223-3p, miR-338-5p, miR-6787-3p, miR-1273h-3p, miR-1288-3p, miR-200c-3p, miR-3074-3p, miR-433-3p, and miR-200b-3p could serve as valuable indicators for monitoring treatment efficacy in patients with TB. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3